{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:47:30Z","timestamp":1791686850433,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":280,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101477","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:32:40Z","timestamp":1791660760000},"page":"101477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunotherapy and circulating tumor DNA in HPV-positive oropharyngeal cancer: a systematic review and exploratory meta-analysis of survival and surveillance outcomes"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5427-5419","authenticated-orcid":false,"given":"Mohammad Mahmoud","family":"Aouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Tam\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A.","family":"El-Shirbeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdel-Maboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korn\u00e9l","family":"D\u00e1nos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101477_bib0001","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0002","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","article-title":"Epidemiology of human papillomavirus\u2013positive head and neck squamous cell carcinoma","volume":"33","author":"Gillison","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0003","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0004","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101477_bib0005","article-title":"Trends in human papillomavirus\u2013associated cancers \u2014 United States, 1999\u20132015","volume":"67","author":"Dyne","year":"2018","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.ctarc.2026.101477_bib0006","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2024.1685","article-title":"Epidemiological and clinical description of patients with oropharyngeal cancer treated in a public oncology referral hospital in Chile","volume":"18","author":"Carvajal","year":"2024","journal-title":"ECancerMedicalScience"},{"key":"10.1016\/j.ctarc.2026.101477_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1197287","article-title":"Burden and geographic distribution of oral cavity and oropharyngeal cancers in the Russian Federation","volume":"13","author":"Muntyanu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0008","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","article-title":"Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis","volume":"24","author":"Mehanna","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0009","article-title":"Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial","author":"Hanna","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101477_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00129","article-title":"Prognostic impact of AJCC\/UICC 8th edition new staging rules in oropharyngeal squamous cell carcinoma","volume":"7","author":"W\u00fcrdemann","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0011","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s11864-023-01050-x","article-title":"Immunotherapy in HPV-related oropharyngeal cancers","volume":"24","author":"Roof","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0012","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03663-z","article-title":"Efficacy of immune checkpoint inhibitors differs in various status of carcinoma: a study based on 29 cohorts with 3255 participants","volume":"73","author":"Wu","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ctarc.2026.101477_bib0013","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hed.24100","article-title":"The education committee of American head and neck society (AHNS), AHNS series\u2014do you know your guidelines? Guideline recommended follow-up and surveillance of head and neck cancer survivors","volume":"38","author":"Roman","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.ctarc.2026.101477_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100316","article-title":"Circulating biomarkers in HPV-associated oropharyngeal cancer: clinical applications of liquid biopsy in diagnosis, prognosis, and surveillance","volume":"9","author":"Kumari","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.ctarc.2026.101477_bib0015","article-title":"Personalizing surveillance in head and neck cancer","author":"Hanna","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.ctarc.2026.101477_bib0016","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101477_bib0017","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101477_bib0018","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101477_bib0019","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer","volume":"25","author":"Chera","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101477_bib0020","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/annonc\/mdy251","article-title":"Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer","volume":"29","author":"Hanna","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0021","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1158\/1078-0432.CCR-23-1478","article-title":"Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance","volume":"29","author":"Hanna","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101477_bib0022","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer","volume":"38","author":"Chera","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0023","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctarc.2026.101477_bib0024","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ctarc.2026.101477_bib0025","article-title":"Prospective phase II trial of definitive chemoradiation and concurrent nivolumab in locally advanced p16+ oropharynx cancer","volume":"10","author":"Regan","year":"2025","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103393","article-title":"Neoadjuvant sintilimab and chemotherapy followed by transoral surgery for HPV-positive resectable oropharyngeal cancer: a single-arm, two-centre, phase 2 trial","volume":"86","author":"Yan","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ctarc.2026.101477_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2025.103807","article-title":"Prognostic implications of HPV cell-free DNA serial testing during follow-up of p16 positive oropharyngeal squamous cell carcinoma after curative-intent treatment","volume":"41","author":"Salati","year":"2025","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0028","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/jamaoncol.2024.1530","article-title":"Neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer","volume":"10","author":"Rosenberg","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0029","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2023.04.014","article-title":"Circulating tumour DNA kinetics in recurrent\/metastatic head and neck squamous cell cancer patients","volume":"188","author":"Taylor","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101477_bib0030","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-21-3849","article-title":"Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Chung","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101477_bib0031","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101477_bib0032","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0033","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ctarc.2026.101477_bib0034","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1\u2013expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101477_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012555","article-title":"Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent\/metastatic HPV16-positive head and neck cancer","volume":"13","author":"Even","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2026.101477_bib0036","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO-24-01580","article-title":"Randomized phase II study of concurrent versus sequential pembrolizumab in combination with chemoradiation in locally advanced head and neck cancer","volume":"43","author":"Zandberg","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0037","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101477_bib0038","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.2014.55.1937","article-title":"Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma","volume":"32","author":"Fakhry","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00052","article-title":"Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy","volume":"7","author":"Canning","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.semcancer.2018.01.008","article-title":"Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments","volume":"52","author":"Solomon","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0041","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00585-25","article-title":"Detection, quantitation, and genotyping of human papillomavirus circulating tumor DNA by droplet digital PCR","volume":"63","author":"Fernholz","year":"2025","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2019.11.014","article-title":"Immune landscape of viral- and carcinogen-driven head and neck cancer","volume":"52","author":"Cillo","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ctarc.2026.101477_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008667","article-title":"Single-cell analysis reveals cellular and molecular factors counteracting HPV-positive oropharyngeal cancer immunotherapy outcomes","volume":"12","author":"Cha","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2026.101477_bib0044","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/jamaoto.2023.1937","article-title":"Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus\u2013associated oropharyngeal cancer","volume":"149","author":"Ferrandino","year":"2023","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.ctarc.2026.101477_bib0045","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hed.25368","article-title":"Detection of circulating HPV16 DNA as a biomarker in the blood of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma","volume":"41","author":"Mazurek","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.ctarc.2026.101477_bib0046","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/atm.2018.03.28","article-title":"Financial toxicity and implications for cancer care in the era of molecular and immune therapies","volume":"6","author":"Tran","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ctarc.2026.101477_bib0047","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv410","article-title":"Minimizing the \u201cfinancial toxicity\u201d associated with cancer care: advancing the research agenda","volume":"108","author":"Tucker-Seeley","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2026.101477_bib0048","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s40425-019-0726-6","article-title":"Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells","volume":"7","author":"Hlad\u00edkov\u00e1","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2026.101477_bib0049","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101477_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102966","article-title":"Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: a systematic review and meta-analysis","volume":"150","author":"Galvis","year":"2020","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"10.1016\/j.ctarc.2026.101477_bib0051","article-title":"Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: a systematic review and meta-analysis","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101477_bib0052","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ijc.28015","article-title":"Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer","volume":"133","author":"Vermeer","year":"2013","journal-title":"Int. J. Cancer"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:19Z","timestamp":1791685339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":52,"alternative-id":["S2468294226003862"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101477","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy and circulating tumor DNA in HPV-positive oropharyngeal cancer: a systematic review and exploratory meta-analysis of survival and surveillance outcomes","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101477"}}